AngioDynamics Files 8-K on Financials

TL;DR

ANGI filed an 8-K, expect financial updates soon.

AI Summary

On October 2, 2025, AngioDynamics, Inc. filed an 8-K report. The filing indicates a current report concerning the company's results of operations and financial condition, as well as Regulation FD disclosures and financial statements. No specific financial figures or events were detailed in the provided text excerpt.

Why It Matters

This filing signals that AngioDynamics is providing updated information regarding its financial performance and operational status to the public and regulatory bodies.

Risk Assessment

Risk Level: low — The filing is a standard procedural report and does not contain information that inherently increases risk.

Key Players & Entities

• ANGIODYNAMICS INC (company) — Registrant
• October 2, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 14 Plaza Drive, Latham, New York 12110 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

• ef20056554_8k.htm (8-K) — 31KB
• ef20056554_ex99-1.htm (EX-99.1) — 514KB
• ef20056554_ex99-2.htm (EX-99.2) — 24KB
• ef20056554_ex99-2slide1.jpg (GRAPHIC) — 81KB
• ef20056554_ex99-2slide2.jpg (GRAPHIC) — 275KB
• ef20056554_ex99-2slide3.jpg (GRAPHIC) — 159KB
• ef20056554_ex99-2slide4.jpg (GRAPHIC) — 109KB
• ef20056554_ex99-2slide5.jpg (GRAPHIC) — 98KB
• ef20056554_ex99-2slide6.jpg (GRAPHIC) — 124KB
• ef20056554_ex99-2slide7.jpg (GRAPHIC) — 137KB
• ef20056554_ex99-2slide8.jpg (GRAPHIC) — 157KB
• ef20056554_ex99-2slide9.jpg (GRAPHIC) — 174KB
• ef20056554_ex99-2slide10.jpg (GRAPHIC) — 27KB
• ef20056554_ex99-2slide11.jpg (GRAPHIC) — 96KB
• ef20056554_ex99-2slide12.jpg (GRAPHIC) — 152KB
• ef20056554_ex99-2slide13.jpg (GRAPHIC) — 67KB
• ef20056554_ex99-2slide14.jpg (GRAPHIC) — 108KB
• 0001140361-25-037060.txt ( ) — 3162KB
• ango-20251002.xsd (EX-101.SCH) — 4KB
• ango-20251002_lab.xml (EX-101.LAB) — 21KB
• ango-20251002_pre.xml (EX-101.PRE) — 16KB
• ef20056554_8k_htm.xml (XML) — 4KB

02 – Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition. On October 2, 2025, AngioDynamics, Inc. ("AngioDynamics") issued a press release announcing financial results for the fiscal first quarter ended August 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. Presentation slides discussing AngioDynamics and its fiscal first quarter ended August 31, 2025 are furnished herewith as Exhibit 99.2. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated October 2, 2025. 99.2 Presentation, dated October 2, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: October 2, 2025 By: /s/ Lawrence T. Weiss Name: Lawrence T. Weiss Title: Senior Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR